Wells Fargo
GLUE icon

Wells Fargo’s Monte Rosa Therapeutics GLUE Stock Holding History

Wells Fargo’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Buy
68,650
+45,439
+196% +$859K ﹤0.01% 3752
2026
Q1 		$382K Sell
23,211
-29,377
-56% -$562K ﹤0.01% 4303
2025
Q4 		$825K Buy
52,588
+16,308
+45% +$220K ﹤0.01% 4117
2025
Q3 		$269K Buy
36,280
+2,583
+8% +$13.7K ﹤0.01% 4753
2025
Q2 		$152K Buy
33,697
+5,142
+18% +$22.9K ﹤0.01% 4931
2025
Q1 		$132K Sell
28,555
-41,607
-59% -$255K ﹤0.01% 4947
2024
Q4 		$487K Buy
70,162
+47,952
+216% +$360K ﹤0.01% 4201
2024
Q3 		$118K Buy
22,210
+5,902
+36% +$29.8K ﹤0.01% 4924
2024
Q2 		$61K Buy
16,308
+3,089
+23% +$15.8K ﹤0.01% 5219
2024
Q1 		$93.2K Buy
13,219
+1,336
+11% +$7.92K ﹤0.01% 4933
2023
Q4 		$67.1K Buy
11,883
+2,127
+22% +$8.34K ﹤0.01% 5147
2023
Q3 		$46.7K Sell
9,756
-3,894
-29% -$25.1K ﹤0.01% 5214
2023
Q2 		$93.5K Buy
13,650
+8,133
+147% +$52.6K ﹤0.01% 5084
2023
Q1 		$43K Buy
+5,517
New +$38.4K ﹤0.01% 5243
2022
Q4 		– Sell
-80
Closed -$1K – 7559
2022
Q3 		$1K Sell
80
-173
-68% -$1.59K ﹤0.01% 6346
2022
Q2 		$2K Sell
253
-15,491
-98% -$156K ﹤0.01% 6317
2022
Q1 		$221K Sell
15,744
-36
-0.2% -$500 ﹤0.01% 4922
2021
Q4 		$322K Buy
15,780
+15,723
+27,584% +$329K ﹤0.01% 4998
2021
Q3 		$1K Buy
+57
New +$1.63K ﹤0.01% 6707

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wells Fargo's GLUE Position: Q2 2026 in Review

Wells Fargo increased its Monte Rosa Therapeutics (GLUE) stake by 196% in Q2 2026, buying an estimated $859K and bringing the position to 68,650 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3752.

Wells Fargo first reported a position in GLUE in Q3 2021 and has held it in 19 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Wells Fargo held 68,650 shares of Monte Rosa Therapeutics worth $1.66M as of Q2 2026.
  • Wells Fargo bought 45,439 Monte Rosa Therapeutics shares in Q2 2026, an estimated $859K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3752 holding.
  • Wells Fargo first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.